Dolutegravir Sodium/Lamivudine
Brand name: Dovato
Rank #101 of 500 drugs by total cost
$173.3M
Total Cost
56,930
Total Claims
$173.3M
Total Cost
1,284
Prescribers
$3,044
Cost per Claim
3,656
Beneficiaries
58,658
30-Day Fills
$135K
Avg Cost/Provider
44
Avg Claims/Provider
About Dolutegravir Sodium/Lamivudine
Dolutegravir Sodium/Lamivudine (sold as Dovato) was prescribed 56,930 times by 1,284 Medicare Part D providers in 2023, costing the program $173.3M. At $3,044 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 98 | Vibegron (Gemtesa) | $185.2M | 283,953 |
| 99 | Omeprazole (Omeprazole) | $182.7M | 12,147,266 |
| 100 | Amlodipine Besylate (Amlodipine Besylate) | $180.1M | 20,835,727 |
| 101 | Dolutegravir Sodium/Lamivudine (Dovato) | $173.3M | 56,930 |
| 102 | Potassium Chloride (Klor-Con M20) | $172.6M | 6,137,143 |
| 103 | Darunavir/Cob/Emtri/Tenof Alaf (Symtuza) | $172.5M | 34,812 |
| 104 | Tamsulosin Hcl (Tamsulosin Hcl) | $168.5M | 8,367,036 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology